A phase I pilot, pharmacokinetics and safety/tolerability study of Renown's sub-lingual apomorphine spray

Trial Profile

A phase I pilot, pharmacokinetics and safety/tolerability study of Renown's sub-lingual apomorphine spray

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Apomorphine (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 03 Apr 2017 New trial record
    • 07 Mar 2017 Results published in the Renown Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top